Clinical trials: Pneumonia, Bacterial
Pneumococcal Disease
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults…
- Trial name
- NCT07284654
- Testing
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Where
- 30 sites in United States
- Volunteers
- 4,049 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumonia
A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia
Pneumonia, or lung infection, is usually treated with antibiotics targeted against the organisms that the physician guesses are causing the problem. The determination of the exact cause of a patient's pneumonia is difficult.
- Trial name
- NCT00867841
- Testing
- nasopharyngeal swab
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Hospital of Eastern Ontario
ARDS (Acute Respiratory Distress Syndrome)
BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics
Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema.
- Trial name
- BALance (NCT07633366)
- Testing
- sampling blood, Lavage with physiologic saline solution
- Where
- Austria
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Pneumocystis, Immunocompromised Patients
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
- Trial name
- OPTIJIROVEC (NCT06890078)
- Testing
- Biological sampling
- Where
- 4 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV-1-infection, Pneumocystis Pneumonia
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
Cotrimoxazole preventive therapy (CPT) is recommended for prevention of morbidity and mortality due to Pneumocystis pneumonia and other infections in HIV positive patients with low immunity.
- Conditions
- HIV-1-infection, Pneumocystis Pneumonia, Opportunistic Infections, Preventive Therapy
- Trial name
- CoTrimResist (NCT03087890)
- Testing
- Cotrimoxazole
- Where
- 6 sites in Tanzania
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Stunting, Underweight
Spirulina Supplementation and Infant Growth, Morbidity and Motor Development
Background: In developing countries, micronutrient deficiency in infants is associated with growth faltering, morbidity, and delayed motor development.
- Conditions
- Stunting, Underweight, Pneumonia, Pneumocystis, Cough
- Trial name
- NCT03523182
- Testing
- Spirulina, Control
- Where
- Zambia
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Programme Against Malnutrition
Childhood Pneumonia, Mycoplasma Pneumonia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and…
- Conditions
- Childhood Pneumonia, Mycoplasma Pneumonia, Antibody-secreting Cells, Enzyme-linked Immunospot (ELISpot)
- Trial name
- myCAP (NCT03613636)
- Testing
- Enzyme-linked immunospot (ELISpot) assay [Blood]
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Pneumonia, Pneumonia - Bacterial
Urine Pneumococcal Antigen Project
Background: Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa.
- Trial name
- UPAP (NCT07181200)
- Where
- Malawi
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Pulmonary Nodule, Invasive Fungal Infections
Granulomatous Pneumocystis Pneumonia
The intra-alveolar form of Pneumocystis jiroveci pneumonia (PjP) is a common pathology in immunocompromised patients, particularly those infected with HIV. The diagnosis is based on the detection of Pj in a LBA.
- Conditions
- Pulmonary Nodule, Invasive Fungal Infections, Pneumocystis Jirovecii
- Trial name
- NC (NCT03731156)
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Pneumococcal Infections, Pneumonia, Pneumococcal
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.
- Trial name
- NCT02116998
- Testing
- GEN-004 with Aluminum Hydroxide Adjuvant, Streptococcus pneumoniae inoculation
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
Subjects will be recruited and divided into 3 groups: 1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4; 2. Control Group A (408 subjects): IIV4 only; 3.
- Trial name
- NCT04559204
- Testing
- IIV4 and PPV23, IIV4, PPV23
- Where
- 4 sites in China
- Volunteers
- 1,224 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumococcal Pneumonia
Targeting of Immune Response After Pneumococcal Vaccination
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate…
- Trial name
- PncHR (NCT01402245)
- Testing
- Pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine
- Where
- 4 sites in Finland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Interstitial Lung Disease, Systemic Autoimmune Disease
ILD-SARDs Registry and Biorepository
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways.
- Conditions
- Interstitial Lung Disease, Systemic Autoimmune Disease, Rheumatic Diseases, Rheumatic Arthritis
- Trial name
- ILD-SARDs (NCT05007340)
- Testing
- Blood draws, Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid), Clinical data collection
- Where
- Canada
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Pneumonia, Pneumococcal, Myocardial Ischemia
Myocardial Injury and Severe Pneumococcal Pneumonia
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery…
- Trial name
- NEUMOCAR (NCT03058211)
- Testing
- Echocardiography, Cardiac Magnetic resonance
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Alejandro Rodriguez Oviedo , MD
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland